Synergistic anti-proliferative effects of combination of ABT-263 and MCL-1 selective inhibitor A-1210477 on cervical cancer cell lines.

about

MCL-1 inhibition in cancer treatment

P2860

Q58694408-881ABE13-5F6C-425B-94AC-FEBAF78D86A2

P2860

Synergistic anti-proliferative effects of combination of ABT-263 and MCL-1 selective inhibitor A-1210477 on cervical cancer cell lines.

Item

http://www.wikidata.org/entity/Q54985966

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Synergistic anti-proliferative ...... on cervical cancer cell lines.

@en

Synergistic anti-proliferative ...... on cervical cancer cell lines.

@nl

type

Item

label

Synergistic anti-proliferative ...... on cervical cancer cell lines.

@en

Synergistic anti-proliferative ...... on cervical cancer cell lines.

@nl

prefLabel

Synergistic anti-proliferative ...... on cervical cancer cell lines.

@en

Synergistic anti-proliferative ...... on cervical cancer cell lines.

@nl

P1476

Synergistic anti-proliferative ...... on cervical cancer cell lines.

@en

P2093

Angeline En Hui Yek

http://www.w3.org/2001/XMLSchema#string

Benedict Shi Xiang Lian

http://www.w3.org/2001/XMLSchema#string

Hemalata Shuvas

http://www.w3.org/2001/XMLSchema#string

Kalaivani Muniandy

http://www.w3.org/2001/XMLSchema#string

Siti Fairus Abdul Rahman

http://www.w3.org/2001/XMLSchema#string

P2860

Evaluation of cell cycle arrest in estrogen responsive MCF-7 breast cancer cells: pitfalls of the MTS assay

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.

Improved survival with bevacizumab in advanced cervical cancer

Modeling nasopharyngeal carcinoma in three dimensions

Inhibition of KIT-glycosylation by 2-deoxyglucose abrogates KIT-signaling and combination with ABT-263 synergistically induces apoptosis in gastrointestinal stromal tumor.

Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.

P2888

s13104-018-3302-0

P304

197

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13104-018-3302-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Nethia Mohana-Kumaran

P577

2018-03-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1101778246

http://www.w3.org/2001/XMLSchema#string

P698

29580266

http://www.w3.org/2001/XMLSchema#string

P932

5870236

http://www.w3.org/2001/XMLSchema#string

Synergistic anti-proliferative effects of combination of ABT-263 and MCL-1 selective inhibitor A-1210477 on cervical cancer cell lines.

about

P2860

P2860

Synergistic anti-proliferative effects of combination of ABT-263 and MCL-1 selective inhibitor A-1210477 on cervical cancer cell lines.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P932